| Antibody-drug conjugates for cancer therapy: chemistry to clinical implications N Dan, S Setua, V Kashyap, S Khan, M Jaggi, M Yallapu, S Chauhan Pharmaceuticals 11 (2), 32, 2018 | 209 | 2018 |
| Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer S Khan, S Setua, S Kumari, N Dan, A Massey, BB Hafeez, MM Yallapu, ... Biomaterials 208, 83-97, 2019 | 120 | 2019 |
| Gemcitabine Combination Nano Therapies for Pancreatic Cancer K Samanta, S Setua, S Kumari, M Jaggi, MM Yallapu, SC Chauhan Pharmaceutics 11 (11), 574, 2019 | 64 | 2019 |
| Restitution of tumor suppressor microRNA-145 using magnetic nanoformulation for pancreatic cancer therapy S Setua, S Khan, MM Yallapu, SW Behrman, M Sikander, SS Khan, ... Journal of Gastrointestinal Surgery 21 (1), 94-105, 2017 | 45 | 2017 |
| Probing mucin interaction behavior of magnetic nanoparticles VN Boya, R Lovett, S Setua, V Gandhi, PKB Nagesh, S Khan, M Jaggi, ... Journal of colloid and interface science 488, 258-268, 2017 | 35 | 2017 |
| Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer VK Kashyap, Q Wang, S Setua, PKB Nagesh, N Chauhan, S Kumari, ... Journal of Experimental & Clinical Cancer Research 38 (1), 29, 2019 | 31 | 2019 |
| Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment AE Massey, M Sikander, N Chauhan, S Kumari, S Setua, AB Shetty, ... Nanomedicine: Nanotechnology, Biology and Medicine 20, 102027, 2019 | 28 | 2019 |
| Clinical significance of MUC13 in pancreatic ductal adenocarcinoma S Khan, N Zafar, SS Khan, S Setua, SW Behrman, ZE Stiles, MM Yallapu, ... HPB, 2018 | 28 | 2018 |
| Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy A Shetty, PKB Nagesh, S Setua, BB Hafeez, M Jaggi, MM Yallapu, ... ACS Omega, 2020 | 14 | 2020 |
| Targeted and theranostic applications for nanotechnologies S Setua, M Jaggi, MM Yallapu, SC Chauhan Nanotechnologies in Preventive and Regenerative Medicine: An Emerging Big …, 2017 | 14* | 2017 |
| VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway VK Kashyap, N Dan, N Chauhan, Q Wang, S Setua, PKB Nagesh, S Malik, ... Cancer Letters, 2019 | 12 | 2019 |
| miR-145: Revival of a Dragon in Pancreatic Cancer S Setua, S Khan, K Doxtater, MM Yallapu, M Jaggi, SC Chauhan Journal of nature and science 3 (3), 2017 | 6 | 2017 |
| Formulation, development, and in vitro evaluation of a CD22 targeted liposomal system containing a non-cardiotoxic anthracycline for B cell malignancies N Mittal, B Mandal, P Balabathula, S Setua, D Janagam, L Lothstein, ... Pharmaceutics 10 (2), 50, 2018 | 5 | 2018 |
| Targeting MUC13 to overcome the survival mechanisms for improved response to chemotherapy S Setua, S Khan, MM Yallapu, SW Behrman, N Zafar, M Jaggi, ... Cancer Research 77 (13 Supplement), 3427-3427, 2017 | 1 | 2017 |
| Attenuation of pancreatic tumor growth by a small molecule tubulin inhibitor VK Kashyap, BB Hafeez, Q Wang, S Setua, A Massey, A Ganju, ... Cancer Research 77 (13 Supplement), 3216-3216, 2017 | | 2017 |
| Mir-145 based magnetic nanoformulation for pancreatic cancer therapy S Setua, S Khan, MM Yallapu, M Sikander, SW Behrman, M Jaggi, ... Cancer Research 76 (14 Supplement), 1071-1071, 2016 | | 2016 |
| 713 Restitution of Tumor Suppressor miR-145 Using Magnetic Nanoparticles Inhibits Pancreatic Cancer S Setua, SW Behrman, S Khan, MM Yallapu, M Jaggi, SC Chauhan Gastroenterology 150 (4), S1189, 2016 | | 2016 |
Murali YallapuAssociate Professor, University of Texas Rio Grande Valley在 utrgv.edu 的电子邮件经过验证
